ПЕРСПЕКТИВЫ ФАРМАКОТЕРАПИИ БОЛЕЗНИ АЛЬЦГЕЙМЕРА, "Успехи Физиологических Наук"

Zuev, V A; Linkova, N. S.; Кветной, И. М.

doi:10.7868/s0301179818040045

Успехи физиологических наук

2018

DOI: 10.7868/s0301179818040045

|View full text |Cite

ПЕРСПЕКТИВЫ ФАРМАКОТЕРАПИИ БОЛЕЗНИ АЛЬЦГЕЙМЕРА, "Успехи Физиологических Наук"

V A Zuev¹,

N. S. Linkova²,

И. М. Кветной³

Abstract: Болезнь Альцгеймера (БА) является социально-значимым заболеванием. При этом молекулярные механизмы патогенеза БА не установлены и способы ее фармакотерапии требуют дальнейшей разработки. В обзоре описаны существующие и потенциальные лекарственные средства для терапии БА, механизм их действия. Ингибиторы ацетилхолинэстеразы второго поколения (Донепезил, Ривастиг-мин, Галантамин) применяются для улучшения когнитивных функций. Блокатор AMDA-рецепторов Мемантин повышает эффективность синаптической передачи у пацие… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Modern approaches to pharmacotherapy of Alzheimer's disease

Davydov,

Fominykh

2023

SBOSMU

View full text Add to dashboard Cite

Currently, about 50 million people suffer from Alzheimer's disease, and this number will only increase over time. There are only four clinically approved drugs to treat this pathology, which include acetylcholinesterase inhibitors (Rivastigmine, Donepezil, and Galantamine) and one N-methyl-D-aspartic acid receptor antagonist (memantine). Although these drugs have a therapeutic effect by improving the cognitive, functional, and behavioral characteristics of patients, they still relieve symptoms of the disease rather than manifest the links of pathogenesis, including β-amyloid precursor protein and hyperphosphorylated tau protein formed during the cleavage of amyloid precursor protein. This group of drugs also has a number of undesirable effects on the gastrointestinal tract, cardiovascular system and nervous activity. In this regard, new drugs are being developed now, directed against β-amyloid and affecting to reduce its production, aggregation, not allowing it to form plaques, the use of immunization method. There is also hyperphosphorylated tau protein, which is either not allowed to form or is immunized against. In addition to these methods, there are no less interesting ways to fight, such as the use of heat shock inducers, to activate the necessary chaperone family, or to reduce neuroinflammation by inhibiting tumor necrosis factors and using nutraceuticals. But, unfortunately, a large number of drugs cannot yet pass all 3 stages of clinical trials while maintaining their original therapeutic properties and without acquiring undesirable effects. That said, many drugs are either the basis for future drugs or are still participating in clinical trials themselves, showing encouraging results.

show abstract

Modern approaches to pharmacotherapy of Alzheimer's disease

Davydov,

Fominykh

2023

SBOSMU

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

ПЕРСПЕКТИВЫ ФАРМАКОТЕРАПИИ БОЛЕЗНИ АЛЬЦГЕЙМЕРА, "Успехи Физиологических Наук"

Cited by 1 publication

References 37 publications

Modern approaches to pharmacotherapy of Alzheimer's disease

Modern approaches to pharmacotherapy of Alzheimer's disease

Contact Info

Product

Resources

About